Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice

Table 3

Most important adverse events in 75 patients with erlotinib therapy.

Event/therapy line	Second-line (𝑛=32)		Third-line (𝑛=30)		Fourth-line and more-line (𝑛=13)
	Grades 1-2	Grades 3-4	Grades 1-2	Grades 3-4	Grades 1-2	Grades 3-4
All	17 (53.1%)	13 (40.6%)	16 (53.3%)	9 (30.0%)	7 (53.8%)	5 (38.5%)
Rash	16 (50.0%)	6 (18.8%)	16 (53.3%)	5 (16.7%)	7 (53.8%)	2 (15.4%)
Diarrhoea	11 (34.4%)	3 (9.4%)	8 (26.7%)	3 (10.0%)	4 (30.8%)	2 (15.4%)
Emesis	2 (6.3%)	1 (3.1%)	4 (13.3%)	1 (3.3%)	3 (23.1%)	2 (15.4%)
Dyspnea	4 (12.5%)	2 (6.3%)	3 (10.0%)	0 (0%)	1 (7.7%)	1 (7.7%)
Pain	1 (3.1%)	2 (6.3%)	3 (10.0%)	1 (3.3%)	0 (0%)	1 (7.7%)
Neurotoxicity	4 (12.5%)	0 (0%)	2 (6.7%)	0 (0%)	1 (7.7%)	1 (7.7%)
Stomatitis	4 (12.5%)	0 (0%)	2 (6.7%)	0 (0%)	1 (7.7%)	0 (0%)
Alopecia	3 (9.4%)	0 (0%)	2 (6.7%)	1 (3.3%)	1 (7.7%)	0 (0%)
Loss of appetite	1 (3.1%)	1 (3.1%)	4 (13.3%)	1 (3.3%)	0 (0%)	0 (0%)